Skip to Content

Aerie Pharmaceuticals, Inc.

Merger

  • Date:
  • 8/23/2022
  • Company Name:
  • Aerie Pharmaceuticals, Inc.
  • Stock Symbol:
  • AERI
  • Company Name - Buyer:
  • Alcon
  • Stock Symbol - Buyer:
  • ALC
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/22/2022

Case Finder

Locate any case using the tools below.

NEW YORK, August 23, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) (“Aerie”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Alcon (NYSE: ALC) (“Alcon”).

On August 22, 2022, Aerie announced that it had entered into an agreement to be acquired by Alcon in an all-cash deal with an enterprise value of $770 million. Pursuant to the merger agreement, Aerie shareholders are expected to receive $15.25 per share in cash. The deal is scheduled to close in the fourth quarter of 2022.

Bragar Eagel & Squire is concerned that Aerie’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Aerie’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aerie Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: